By: Samiya Luthfia Khaleel --
16 December, 2014
Rare disease affects the patient population of around 350 million with more than 6000 to 7000 unique diseases. The government policies and incentives have triggered the big pharma companies apart from the biotech to show more propensities towards developing orphan drug. There are around 450 orphan drugs in development encompassing different therapeutic areas. Though the phase III costs of conducting an orphan drug development is lesser when compared to non-orphan, rare disease clinical trials encounter a lot of challenges not only in terms of patient recruitment but also retention. This paper discusses technologies or methods that can be incorporated in patient recruitment that will provide successful rare disease patient enrollment and retention.
COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)